Key Decisions Approved

The Board of Directors at their meeting held on May 25, 2026 (commencing at 11:21 AM and concluding at 12:15 PM) approved the following matters:

1. Audited Standalone Financial Results for Q4 and FY Ended March 31, 2026

  • The Board approved the Audited Standalone Financial Results for the fourth quarter and financial year ended March 31, 2026.
  • The statutory auditors, KKC & Associates LLP, issued an audit report with an unmodified opinion for FY 2025-26.
  • Financial Performance Highlights (₹ in million):
  • Revenue from Operations (FY26): ₹10,159.75 million (FY25: ₹10,299.85 million)
  • Total Income (FY26): ₹10,762.41 million (FY25: ₹10,762.41 million)
  • Profit Before Tax (FY26): ₹6,834.63 million (FY25: ₹6,701.42 million)
  • Profit for the Year (FY26): ₹2,478.16 million (FY25: ₹3,052.03 million)
  • Earnings Per Share (Basic) (FY26): ₹14.29 (FY25: ₹17.59)
  • Earnings Per Share (Diluted) (FY26): ₹14.29 (FY25: ₹17.59)
  • Quarterly Performance (Q4 FY26):
  • Revenue from Operations: ₹2,346.68 million
  • Profit for the period: ₹643.44 million
  • EPS (Basic & Diluted): ₹3.71

2. Recommendation of Final Dividend

  • The Board recommended a final dividend of ₹1.2 (60%) per equity share of face value ₹2 each for the financial year ended March 31, 2026.
  • This dividend is subject to approval by members at the ensuing Annual General Meeting (AGM) to be held within the stipulated timeline under the Companies Act, 2013.
  • The record date and dividend payment date will be determined and communicated later.

3. Proposal for Fundraising

  • The Board approved a proposal to raise funds up to ₹10,000 million (Rupees Ten Thousand Million).
  • The funds may be raised through the creation, offering, and issuance of various instruments including:
  • Fully paid-up Equity Shares
  • Fully or partly convertible debentures
  • Other equity-based instruments or securities
  • Convertible preference shares
  • Warrants (detachable or not)
  • Or any combination of the above securities
  • The fundraising may be undertaken through one or more of the following methods:
  • Public issue
  • Preferential issue
  • Private placement
  • Qualified Institutions Placement (QIP)
  • Or any other permissible mode
  • The issuance may be in one or more tranches, with or without a green shoe option.
  • The final terms and conditions will be determined by the Board at its discretion, subject to receipt of necessary approvals including shareholder approval and regulatory/statutory approvals.

4. Re-appointment of Internal Auditors

  • The Board re-appointed M/s. H.H. Chimthanawala & Co., Chartered Accountants, as the Internal Auditors of the Company for the financial year 2026-27.
  • This reappointment was based on the recommendation of the Audit Committee.
  • The firm's registration number is 112363W, and it has no relationship with any directors or KMPs of the Company.

Additional Information

  • The company has scheduled an Extra-Ordinary General Meeting (EGM) on June 17, 2026, at 11:00 AM (IST) through video conferencing/other audio-visual means to seek shareholder approval for the fundraising proposal.
  • The company is engaged in a single reportable business segment per IND AS 108: manufacturing of Artificial Sweetener, Contrast Media Intermediate, Pharma Intermediate, and APIs used in Pharmaceutical and Healthcare products.
  • The company does not have any subsidiaries, associates, or joint ventures as of March 31, 2026, making consolidated financial statements not applicable.
  • The financial results for Q4 FY26 and FY26 are the balancing figures between the audited full-year results and the published unaudited year-to-date figures up to the third quarter.